Healthspan, Lifespan, and the Biology of Aging

Episode Summary

Executive Summary: The episode explores BioAge’s approach to aging as a treatable biology, not an inevitable mystery. Kristen Fortney explains how human biobanks, proteomics, and longitudinal health data helped identify apolin as a longevity-linked target, leading to mouse and early clinical work in muscle aging. The discussion connects aging biology to disease prevention, healthspan, and the long-term promise of extending healthy life.

Main Topics: Kristen Fortney’s founder journey into aging biology (Priority: 5/5): Fortney describes a path from childhood sci-fi interest, to math/physics, to bioinformatics and an aging-focused postdoc, ultimately motivating the founding of BioAge. BioAge’s human-data-first discovery platform (Priority: 5/5): The company began by sourcing rare longitudinal biobanks with decades of blood samples and health records, then using modern omics tools to identify biomarkers and drug targets tied to healthy aging. Apolin as a longevity and muscle-health target (Priority: 5/5): Apolin emerged from proteomics as a blood protein linked to longer life, better muscle, and better cognitive function; the team then validated its relevance through animal studies and a clinical trial. Translating aging biology into therapeutics (Priority: 5/5): The episode emphasizes the value of moving from human associations to mouse validation to human clinical trials, using muscle atrophy and bed-rest studies as a tractable proof-of-mechanism path. Aging as the underlying driver of major disease (Priority: 4/5): Speakers argue aging is a major risk factor for cancer, cardiovascular disease, diabetes, and dementia, and that targeting aging could delay multiple diseases at once rather than treating them individually. The longevity field’s broader scientific and philosophical questions (Priority: 4/5): The conversation covers statins, metformin, rapamycin, partial reprogramming, parabiosis, and whether extending lifespan is desirable or socially disruptive, framing longevity as both a medical and societal issue. Practical advice for newcomers entering bio and health (Priority: 3/5): Fortney advises tech and startup people interested in longevity to attend conferences, talk to scientists, and learn how to distinguish robust findings from hype.

Key Arguments: Aging is a highly tractable area for drug discovery because human longevity differences can reveal biology that matters across many diseases. Human biobanks with decades of samples and linked outcomes can serve as a 50-year experiment for identifying aging-related pathways. Apolin is a strong target because higher middle-aged levels predict longer life, better muscle, and better cognition in a linear way. Mouse models are still useful for de-risking, but starting with human data increases confidence that the target matters in people. Treating aging may have broader impact than curing single diseases, since most major diseases are age-associated and cluster later in life. Aging interventions should prioritize healthspan—years lived in good health—not only total lifespan. Broad clinical benefit may emerge by first approving drugs for narrow indications, then expanding labels over time, similar to the statin playbook. The field is still early, but Fortney believes 10 to 20 additional healthy years may be plausible over time if discoveries translate. New entrants into longevity should build literacy by engaging directly with researchers, not only by reading papers or abstracts.

Data Points: App Store developer payouts: over $320 billion - Mentioned in the host intro while teasing a separate App Store episode Year BioAge co-founder began aging-focused Stanford postdoc: 2012 - Fortney joined an aging biology lab at Stanford after her PhD BioAge founding timeframe: late 2014 / early 2015 - Fortney describes when the company was founded Biobank sample age: up to 50 years old - BioAge sourced rare longitudinal samples collected from healthy middle-aged people Human population size reference: 8 billion examples - Used to describe the scale of human aging data available globally Age-related lean mass loss during bed rest: about 7% in 10 days - Vijay cites rapid muscle loss in older people during bed-rest studies Young-person comparison for similar muscle loss: a couple of months of bed rest - Shows age accelerates muscle wasting Mouse muscle loss in cast model: close to half the weight of their muscle - Very old mice with one arm casted lost substantial muscle mass without protection Average U.S. lifespan: around 80 years - Used in the healthspan versus lifespan discussion Average healthspan in the U.S.: around 60 years - Used to illustrate the gap between living longer and living healthier Life extension from curing all cancer: about 3 to 4 years - Vijay cites a statistic to show cancer cure alone would not dramatically extend average lifespan Potential healthy-life extension from slowing aging: 10 to 20 years - The episode frames this as the field’s aspirational promise Coffee consumption discussed: up to 5 cups/day in retrospective studies - Fortney says stronger observational benefits were seen as intake rose, though data are retrospective Fortney’s coffee intake: 7 to 10 cups/day - She notes this personal habit while discussing coffee studies Aging mouse colony size: 7,000 mice - Fortney references BioAge’s ability to study aged animals Human life expectancy a century ago: mid-40s - Used to show lifespan has already changed dramatically over time

Pivotal Quotes: "What if you could cure all cancers tomorrow? What would that do to the average lifespan?" — Kristen Fortney: Host prompt used to challenge assumptions about how much single-disease cures change longevity "There’s going to be a lot that we can learn about how humans age by studying, you know, the 8 billion examples all around us." — Kristen Fortney: Explains BioAge’s core thesis for using human population data to find aging targets "The average lifespan in the U.S. is around 80 or so. The average health span is around 60." — Vijay Pandey: Defines the distinction between living longer and living healthier

Implications: The episode frames aging as a modifiable biology with major implications for biotech, medicine, and public health. If human-data-driven targets translate, companies could broaden from narrow indications to longer-term longevity and prevention markets, reshaping how disease is treated and how long people stay healthy.